Compare Ingersoll Rand with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INGERSOLL RAND vs INDOCO REMEDIES - Comparison Results

INGERSOLL RAND     Change

Ingersoll Rand is a global diversified industrial company, engaged in the business of providing solutions for infrastructure development, industrial solutions, residential solutions and security technologies. Ingersoll-Rand manufactures a wide range ... More

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INGERSOLL RAND INDOCO REMEDIES INGERSOLL RAND/
INDOCO REMEDIES
 
P/E (TTM) x 25.1 111.3 22.5% View Chart
P/BV x 1.8 1.9 94.1% View Chart
Dividend Yield % 1.0 0.7 130.7%  

Financials

 INGERSOLL RAND   INDOCO REMEDIES
EQUITY SHARE DATA
    INGERSOLL RAND
Mar-18
INDOCO REMEDIES
Mar-18
INGERSOLL RAND/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs940317 296.2%   
Low Rs652178 366.0%   
Sales per share (Unadj.) Rs194.7113.1 172.2%  
Earnings per share (Unadj.) Rs28.24.5 630.4%  
Cash flow per share (Unadj.) Rs32.111.8 272.1%  
Dividends per share (Unadj.) Rs6.001.00 600.0%  
Dividend yield (eoy) %0.80.4 186.8%  
Book value per share (Unadj.) Rs357.573.2 488.0%  
Shares outstanding (eoy) m31.5792.15 34.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.12.2 186.5%   
Avg P/E ratio x28.355.5 51.0%  
P/CF ratio (eoy) x24.821.0 118.1%  
Price / Book Value ratio x2.23.4 65.8%  
Dividend payout %21.322.4 95.2%   
Avg Mkt Cap Rs m25,12822,830 110.1%   
No. of employees `0000.75.5 12.7%   
Total wages/salary Rs m1,0612,209 48.0%   
Avg. sales/employee Rs Th8,858.61,910.1 463.8%   
Avg. wages/employee Rs Th1,528.8405.0 377.5%   
Avg. net profit/employee Rs Th1,280.875.5 1,697.5%   
INCOME DATA
Net Sales Rs m6,14810,419 59.0%  
Other income Rs m71447 1,522.2%   
Total revenues Rs m6,86210,466 65.6%   
Gross profit Rs m7081,349 52.5%  
Depreciation Rs m126677 18.6%   
Interest Rs m-21235 -8.8%   
Profit before tax Rs m1,317484 272.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m42872 590.6%   
Profit after tax Rs m889412 216.0%  
Gross profit margin %11.512.9 88.9%  
Effective tax rate %32.515.0 217.1%   
Net profit margin %14.54.0 366.0%  
BALANCE SHEET DATA
Current assets Rs m9,9165,373 184.5%   
Current liabilities Rs m1,5934,157 38.3%   
Net working cap to sales %135.411.7 1,160.0%  
Current ratio x6.21.3 481.7%  
Inventory Days Days4668 68.2%  
Debtors Days Days6573 89.7%  
Net fixed assets Rs m1,2206,244 19.5%   
Share capital Rs m316184 171.3%   
"Free" reserves Rs m10,9696,566 167.1%   
Net worth Rs m11,2856,750 167.2%   
Long term debt Rs m01,233 0.0%   
Total assets Rs m12,88812,363 104.2%  
Interest coverage x-62.33.1 -2,036.6%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.50.8 56.6%   
Return on assets %6.75.2 128.8%  
Return on equity %7.96.1 129.2%  
Return on capital %11.59.0 127.5%  
Exports to sales %24.40-   
Imports to sales %20.70-   
Exports (fob) Rs m1,502NA-   
Imports (cif) Rs m1,275NA-   
Fx inflow Rs m1,5023,762 39.9%   
Fx outflow Rs m1,5741,143 137.7%   
Net fx Rs m-722,619 -2.7%   
CASH FLOW
From Operations Rs m7711,227 62.9%  
From Investments Rs m935-1,360 -68.7%  
From Financial Activity Rs m-231-388 59.6%  
Net Cashflow Rs m1,475-521 -283.4%  

Share Holding

Indian Promoters % 0.0 59.2 -  
Foreign collaborators % 74.0 0.0 -  
Indian inst/Mut Fund % 7.2 12.5 57.6%  
FIIs % 0.5 6.0 8.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 18.3 22.4 81.7%  
Shareholders   19,522 12,805 152.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INGERSOLL RAND With:   GEOJIT FINANCIAL SERVICES  KOTHARI PRODUCTS  NESCO  JSW HOLDINGS  GREENPLY INDUSTRIES  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

INGERSOLL RAND Announces Quarterly Results (1QFY20); Net Profit Down 8.0% (Quarterly Result Update)

Aug 16, 2019 | Updated on Aug 16, 2019

For the quarter ended June 2019, INGERSOLL RAND has posted a net profit of Rs 191 m (down 8.0% YoY). Sales on the other hand came in at Rs 2 bn (up 17.3% YoY). Read on for a complete analysis of INGERSOLL RAND's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INGERSOLL RAND Announces Quarterly Results (4QFY19); Net Profit Down 36.4% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, INGERSOLL RAND has posted a net profit of Rs 168 m (down 36.4% YoY). Sales on the other hand came in at Rs 2 bn (up 40.4% YoY). Read on for a complete analysis of INGERSOLL RAND's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INGERSOLL RAND SHARE PRICE


Oct 15, 2019 03:37 PM

TRACK INGERSOLL RAND

  • Track your investment in INGERSOLL RAND with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INGERSOLL RAND

INGERSOLL RAND 8-QTR ANALYSIS

COMPARE INGERSOLL RAND WITH

MARKET STATS